HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug

MT Newswires Live

Jan 02, 2025

HighTide Therapeutics (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.

The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.

Final data from the trial is expected to come out in 2025, the filing said.

Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2500918776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500918776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500918776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 15:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500918776","market":"hk","top_or_hot":-1,"title":"HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug","media":"MT Newswires Live","content":"<html><body><p> HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.</p><p>The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.</p><p>Final data from the trial is expected to come out in 2025, the filing said.</p><p>Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-02 15:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HighTide <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.</p><p>The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.</p><p>Final data from the trial is expected to come out in 2025, the filing said.</p><p>Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500918776","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500918776","pubTimestamp":1735802352,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HighTide Therapeutics  completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate , for the treatment of patients with type 2 diabetes mellitus.The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.Final data from the trial is expected to come out in 2025, the filing said.Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B","LENZ":"Therapeutics","BK1161":"生物科技","BK4139":"生物科技"},"translate_title":"HighTide Therapeutics招募患者进行代谢、消化系统疾病药物的3期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"02511":0.9},"content_text":"HighTide Therapeutics (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.Final data from the trial is expected to come out in 2025, the filing said.Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}